Protos: The first dual-action bone agent for osteoporosis

Editorial office

Abstract


Servier Laboratories recently announced the launch of its new osteoporosis drug Protos (strontium ranelate) in South Africa. Indicated for the treatment of postmenopausal osteoporosis to reduce the risk of both vertebral and non-vertebral fractures, including the hip,1 Protos is a new first-line option in the treatment of postmenopausal osteoporosis.

Full Text: PDF


This journal is hosted by: OpenJournals Publishing. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License